GlassScriptPhysician profile
Sandy Ting Liu
NPI 1174808224
$397,539.19
in general payments reported to CMS, 2019-2025
41 companies · $65K in 2025
The $65K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $18K · 2021: $77K · 2022: $58K · 2023: $84K · 2024: $61K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $64K · Travel and Lodging: $25K · Consulting Fee: $8,124 · Food and Beverage: $6,555 · Honoraria: $2,310 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,552.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $64,125.00 |
| Travel and Lodging | $25,190.33 |
| Consulting Fee | $8,123.75 |
| Food and Beverage | $6,555.45 |
| Honoraria | $2,310.00 |
| Education | $113.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $189,746.01 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $52,103.30 | 2019-2025 | Padcev, Xtandi |
| Eisai INC. | $50,751.75 | 2019-2025 | |
| Seagen INC. | $33,446.71 | 2020-2023 | Padcev |
| Emd Serono, INC. | $20,003.58 | 2020-2023 | Bavencio |
| Merck Sharp & Dohme LLC | $13,435.97 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Aveo Pharmaceuticals, INC. | $6,644.68 | 2021-2023 | Fotivda |
| Janssen Biotech, INC. | $5,903.91 | 2019-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $4,797.37 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,636.83 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,343.59 | 2019-2025 | Truqap |
| Janssen Scientific Affairs, LLC | $2,369.58 | 2021-2024 | Erleada, Akeega |
| E.R. Squibb & Sons, L.L.C. | $1,729.00 | 2021 | |
| Astellas Pharma Global Development | $1,511.68 | 2021-2023 | Xtandi |
| Biohaven Pharmaceutical Holding Company LTD. | $1,500.10 | 2022 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.